Chiron Capital Management, LLC Tg Therapeutics, Inc. Transaction History

Chiron Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	SELL	$15.48 - $35.0 $40,248 - $91,000	-2,600 Reduced 21.49%	9,500 $235,000
Q1 2023 Apr 21, 2023	BUY	$10.23 - $19.34 $15,171 - $28,681	1,483 Added 13.97%	12,100 $181,000
Q4 2022 Jan 23, 2023	BUY	$5.01 - $11.83 $53,191 - $125,599	10,617 New	10,617 $0
Q2 2022 Jul 25, 2022	SELL	$3.74 - $10.66 $11,126 - $31,713	-2,975 Reduced 21.73%	10,717 $46,000
Q1 2022 Apr 18, 2022	BUY	$7.81 - $20.45 $14,995 - $39,264	1,920 Added 16.31%	13,692 $130,000
Q4 2021 Jan 18, 2022	BUY	$15.2 - $35.51 $178,934 - $418,023	11,772 New	11,772 $224,000
Q4 2020 Mar 05, 2021	SELL	$25.27 - $54.9 $111,819 - $242,932	-4,425 Closed	0 $0
Q3 2020 Nov 19, 2020	BUY	$18.49 - $27.24 $81,818 - $120,537	4,425 New	4,425 $118,000

336

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Chiron Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Chiron Capital Management, LLC with notifications on news.